Literature DB >> 20554747

Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer.

Hiroshi Hirata1, Yuji Hinoda, Mohd S Zaman, Yi Chen, Koji Ueno, Shahana Majid, Christina Tripsas, Mary Rubin, Lee-May Chen, Rajvir Dahiya.   

Abstract

Endometrial cancer (EC) is a steroid hormone-dependent cancer. Uridine 5'-diphospho-glucuronosyltransferase enzymes conjugate and detoxify endogenous and exogenous steroid hormones and environmental carcinogens. Among these enzymes, the function of UGT2B17 is unknown except for glucuronidation. The messenger RNA expression of UGT2B17 and myeloid cell leukemia-1 (Mcl-1) was significantly increased in EC tissues compared with matched normal endometrial tissues. Therefore, we focused on the function of UGT2B17 in EC. A total of nine patients with confirmed EC were enrolled in this study to investigate the expression of UGT2B17 and target genes. EC cell lines were used for functional tests including cell growth, invasion, apoptosis and cell cycle analyses. To find the target genes of UGT2B17, we performed microarray analysis to see which genes were upregulated or downregulated by UGT2B17-transfected cells. Functional analysis showed decreased numbers of viable cells and increased numbers of apoptotic cells in si-UGT2B17-transfected Ishikawa cells. Among microarray target genes, Mcl-1 was significantly downregulated in si-UGT2B17-transfected cells. We also found upregulation of Puma protein, a target of Mcl-1, in si-UGT2B17-transfected cells. This is the first report to show that UGT2B17 and Mcl-1 expression are upregulated in EC tissues and that UGT2B17 depletion induces inhibition of cell growth and apoptosis in EC cells through Mcl-1 downregulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554747      PMCID: PMC2930802          DOI: 10.1093/carcin/bgq124

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  35 in total

Review 1.  Clearing the TRAIL for Cancer Therapy.

Authors:  Mark A Hall; John L Cleveland
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

2.  Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.

Authors:  Jong Park; Lan Chen; Luke Ratnashinge; Thomas A Sellers; Jean-Paul Tanner; Ji-Hyun Lee; Nicole Dossett; Nicholas Lang; Fred F Kadlubar; Christine B Ambrosone; Babu Zachariah; Randy V Heysek; Stephen Patterson; Julio Pow-Sang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

Review 3.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence.

Authors:  P I Mackenzie; I S Owens; B Burchell; K W Bock; A Bairoch; A Bélanger; S Fournel-Gigleux; M Green; D W Hum; T Iyanagi; D Lancet; P Louisot; J Magdalou; J R Chowdhury; J K Ritter; H Schachter; T R Tephly; K F Tipton; D W Nebert
Journal:  Pharmacogenetics       Date:  1997-08

Review 4.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily.

Authors:  Peter I Mackenzie; Karl Walter Bock; Brian Burchell; Chantal Guillemette; Shin-ichi Ikushiro; Takashi Iyanagi; John O Miners; Ida S Owens; Daniel W Nebert
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

5.  TRAIL resistance results in cancer progression: a TRAIL to perdition?

Authors:  H Malhi; G J Gores
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

6.  Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells.

Authors:  William R Harrington; Surojeet Sengupta; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2006-05-11       Impact factor: 4.736

Review 7.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.

Authors:  Daniel W Nebert; Timothy P Dalton
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

8.  Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects.

Authors:  Robert A Smith; Vilma Cokkinides; Harmon J Eyre
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

9.  Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids.

Authors:  M Beaulieu; E Lévesque; D W Hum; A Bélanger
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

10.  The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer.

Authors:  Carla J Gallagher; Joshua E Muscat; Amy N Hicks; Yan Zheng; Anne-Marie Dyer; Gary A Chase; John Richie; Philip Lazarus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-04       Impact factor: 4.254

View more
  12 in total

1.  UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?

Authors:  Sujata Bhoi; Panagiotis Baliakas; Diego Cortese; Mattias Mattsson; Marie Engvall; Karin E Smedby; Gunnar Juliusson; Lesley-Ann Sutton; Larry Mansouri
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

2.  Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.

Authors:  Ebrahim Eskandari-Nasab; Mohammad Hashemi; Hamzeh Rezaei; Aliakbar Fazaeli; Mohammad Ali Mashhadi; Simin Sargholzaei Moghaddam; Farshid Arbabi; Mahdi Jahantigh; Mohsen Taheri
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

Review 3.  Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.

Authors:  Ailin Zhang; Jiawei Zhang; Stephen Plymate; Elahe A Mostaghel
Journal:  Horm Cancer       Date:  2016-01-21       Impact factor: 3.869

Review 4.  Role of non-HLA gene polymorphisms in graft-versus-host disease.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2013-08-15       Impact factor: 2.490

Review 5.  An Evolutionary Perspective on the Impact of Genomic Copy Number Variation on Human Health.

Authors:  Marie Saitou; Omer Gokcumen
Journal:  J Mol Evol       Date:  2019-09-14       Impact factor: 2.395

6.  Transcriptome analysis using next generation sequencing reveals molecular signatures of diabetic retinopathy and efficacy of candidate drugs.

Authors:  Raj P Kandpal; Harsha K Rajasimha; Matthew J Brooks; Jacob Nellissery; Jun Wan; Jiang Qian; Timothy S Kern; Anand Swaroop
Journal:  Mol Vis       Date:  2012-05-02       Impact factor: 2.367

7.  MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.

Authors:  Yosuke Konno; Peixin Dong; Ying Xiong; Fumihiko Suzuki; Jiabin Lu; Muyan Cai; Hidemichi Watari; Takashi Mitamura; Masayoshi Hosaka; Sharon J B Hanley; Masataka Kudo; Noriaki Sakuragi
Journal:  Oncotarget       Date:  2014-08-15

8.  Effect of Dose and 5α-Reductase Inhibition on the Circulating Testosterone Metabolite Profile of Men Administered Oral Testosterone.

Authors:  Abdul Basit; John K Amory; Bhagwat Prasad
Journal:  Clin Transl Sci       Date:  2018-06-19       Impact factor: 4.689

9.  Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.

Authors:  Deepak Kumar Bhatt; Abdul Basit; Haeyoung Zhang; Andrea Gaedigk; Seung-Been Lee; Katrina G Claw; Aanchal Mehrotra; Amarjit Singh Chaudhry; Robin E Pearce; Roger Gaedigk; Ulrich Broeckel; Timothy A Thornton; Deborah A Nickerson; Erin G Schuetz; John K Amory; J Steven Leeder; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2018-03-30       Impact factor: 3.922

10.  Copy Number Variation of UGT 2B Genes in Indian Families Using Whole Genome Scans.

Authors:  Avinash M Veerappa; Prakash Padakannaya; Nallur B Ramachandra
Journal:  J Nucleic Acids       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.